IL-15 and B7 co-stimulation

This podcast delves into the exciting world of cancer immunotherapy, focusing on the evolution of cancer vaccines and the recent surge of cell-based therapies. This series follows a string of primary research papers highlighting the most impactful advances in CAR T Cell therapy. It is a companion to a KU Edwards Campus Biotechnology course, but it contains information interesting to anyone who wants to understand the mechanics of this therapy. Like the last episode, this paper endeavors to solve the problem of Activation-induced cell death (AICD) amongst recombinant, antigen-directed T Cells. Both papers considered CD28 co-stimulation by B7.1, with Maher et al electing for CD28 incorporation into the antigen receptor, and this paper relying on B7 expression by target cells. This paper also incorporates the addition of IL-15 as supportive of the long-term survival of the T Cells.